Endpoints winners and losers 2024: Best and worst biotech trendsnews2024-12-19T14:00:55+00:00December 19th, 2024|Endpoints News|
US drug spending surged to almost $450B in 2023news2024-12-18T21:00:33+00:00December 18th, 2024|Endpoints News|
Novartis, AbbVie and PhRMA secure 340B court win in West Virginianews2024-12-18T19:44:19+00:00December 18th, 2024|Endpoints News|
Merck’s long-awaited obesity move is an oral GLP-1 from Chinanews2024-12-18T15:18:50+00:00December 18th, 2024|Endpoints News|
Novartis and BioAge partner on longevity, exercise targetsnews2024-12-18T14:00:19+00:00December 18th, 2024|Endpoints News|
Jazz Pharmaceuticals CEO and co-founder announces retirementnews2024-12-17T20:42:09+00:00December 17th, 2024|Endpoints News|
Major PBM reforms feature in Congress’ year-end spending billnews2024-12-17T20:26:20+00:00December 17th, 2024|Endpoints News|
Sandoz agrees to $275M settlement in generic antitrust litigationnews2024-12-17T20:14:37+00:00December 17th, 2024|Endpoints News|
Pfizer projects stability for 2025 amid turbulence in DCnews2024-12-17T17:28:58+00:00December 17th, 2024|Endpoints News|
Employee lawsuit over J&J’s own health costs may loosen PBMs’ gripnews2024-12-17T14:30:14+00:00December 17th, 2024|Endpoints News|
